Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male

Inclusion Criteria: * BMI: 18.0 - 27.0 kg/m2 * Willingness to sign the written Informed Consent Form Exclusion Criteria: * Evidence of clinically relevant pathology * History of relevant drug and food allergies * Positive screen on drugs of abuse * Participation in a drug study within 60 days prior to drug administration.